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Rates ofmorbidity andmortality fromcardiovascular disease are high in patientswith rheumatoid arthri-
tis (RA); however, the mechanisms and biomarkers that reﬂect coronary plaque vulnerability have not
yet been established. We present a case of acute coronary syndrome (ACS) presumably caused by exac-
erbation of chronic inﬂammation of RA, in which an abrupt increase in serum triglyceride was seen on
the day of onset of ACS but not during effort angina. This case suggests that RA patients with an abruptcute coronary syndrome
riglyceride
umor necrosis factor-
iomarker
increase in triglyceride need intensive care including anti-platelet and statin therapy for the prevention
of coronary plaque rupture.
<Learning objective: Triglyceride might be a sensitive biomarker of activated macrophages and plaque
vulnerability in patientswith RA. RA patientswith an abrupt increase in triglyceridemight need intensive
care including anti-platelet and statin therapy for the prevention of coronary plaque rupture.>
© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.ntroduction
Rheumatoid arthritis (RA) is a chronic progressive inﬂamma-
ory joint disorder. Vasculitis is the most serious complication of
A leading to severe extra-articular organ failure due to microvas-
ular insufﬁciency, which can result in a fatal outcome [1]. Patients
ith RA suffer signiﬁcant morbidity and mortality from cardiovas-
ular disease (CVD) [2,3]. CVDassociatedwithRA includes coronary
rtery disease, stroke, congestive heart failure, and peripheral arte-
ial disease, which are presumably caused by chronic vasculitis
ue to endothelial dysfunction; however, the precise mechanism
y which an inﬂammatory joint accelerates endothelial dysfunc-
ion has not been clariﬁed [4]. In addition, biomarkers that reﬂect
oronary plaque vulnerability have not yet been established. Here,
∗ Corresponding author at: 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
el.: +81 88 633 7851; fax: +81 88 633 7894.
E-mail address: syagi@tokushima-u.ac.jp (S. Yagi).
ttp://dx.doi.org/10.1016/j.jccase.2014.04.009
878-5409/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights rewe present a case of acute coronary syndrome (ACS) presumably
caused by exacerbation of chronic inﬂammation of RA, in which an
abrupt increase in serum triglyceride was seen on the day of onset
of ACS.
Case report
A 72-year-old man was admitted to our hospital in August
2007 for sudden onset of chest pain at rest and was brought to
the emergency room of our hospital by ambulance. He had a
history of diabetes and hyperlipidemia for 25 years and a history
of RA complicated with rheumatoid vasculitis for 18 years and
had been prescribed 15mg of prednisolone and 50mg of azathio-
prine daily. A 12-lead electrocardiogram on admission showed
elevation of ST in leads V2–4 and depression of ST in leads II and
aVF (Fig. 1A). ACS was therefore suspected. Emergency coronary
angiography showed 99% stenosis with thrombosis at the proximal
left anterior descending coronary artery (Fig. 1B). Thrombus aspi-
ration and implantation of a bare metal stent (3.0mm×30mm)
served.
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aig. 1. (A) Twelve-lead electrocardiogram on admission. (B) Emergency coronary an
rtery (arrow). LCA, left coronary artery; RCA, right coronary artery.
ere performed successfully, and creatine kinase peaked at
627U/L. Pathohistology of the thrombus showed accumulation
f CD68-positive and CD3-negative inﬂammatory cells, indicating
acrophage-dominant accumulation of inﬂammatory cells (Fig. 2).
Hyperlipidemia and diabetes had been controlled well with0mgof atorvastatin and insulin therapy, respectively. RAhadbeen
ontrolled with an adrenocortical steroid and immunosuppress-
nt. However, the patient had gradually felt exacerbation of joint
ymptoms several months before the onset of ACS. The results of
ig. 2. Aspirated thrombus fromthecoronaryartery showsaccumulationofmacrophage-d
or CD68. (C) Immunohistochemistry for CD3. The coronary artery from necropsy showe
dipose tissue. (D) Hematoxylin and eosin staining of neointima. (E) CD68 staining of neophy showed 99% stenosis with thrombosis at the left anterior descending coronary
C-reactive protein (CRP) and rheumatoid arthritis particle agglu-
tination (RAPA) tests showed elevation on the day of onset of
ACS. Other inﬂammatory diseases including bacterial endocarditis,
tumor, liver disease (acute and chronic hepatitis), and rheumatic
fever were excluded from the medical interview and from labo-
ratory and echographic ﬁndings. Of note, well-controlled fasting
triglyceride had gradually increased 5 months before the onset
of ACS and peaked at 626mg/dL at the onset of ACS without any
over-caloric intake (Fig. 3).
ominant inﬂammatory cells. (A)Hematoxylin andeosin. (B) Immunohistochemistry
d accumulation of CD68-positive inﬂammatory cells in neointima and pericoronal
intima. (F) CD68 staining of pericoronal adipose tissue. Black bar in A–F 100m.
56 S. Yagi et al. / Journal of Cardiology Cases 10 (2014) 54–57
1    2    3   4    5    6   7   8    9   10  11 6    7    8    9  10  11 124    52    3 12   1   (Month)
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
0
200
400
600
800
CRP(mg/dL)
(%)HbA1c
RAPA<40RAPA>20480RAPA<40
ACS Eﬀort angina
RAPA<40
Triglyceride(mg/dL)
LDL-Cholesterol(mg/dL)
F e and e
s reactiv
t
1
v
n
b
t
w
a
c
s
o
o
a
t
D
i
d
l
j
t
b
t
u
T
R
t
o
t
b
b
vulnerability of coronary plaque leading toACS (Fig. 4). The concept
is consistent with a report showing that a high triglyceride level is
related toahigh level of systemic inﬂammation inRApatients [7]. In
TNF-α from synovial ssue
Acvaon of synovis
Endothelial 
lipoprotein lipase 
FFA from 
peripheral ssues
TG synthesis 
in the liver
TG  catabolism  
Macrophage 
acvaon
Adipocyte lipolysis
MMP releaseig. 3. Biomarkers during the clinical course of the onset of acute coronary syndrom
yndrome; LDL, low-density lipoprotein; HbA1c, glycated hemoglobin A1c; CRP, C-
CRP was decreased by 0.59mg/dL and low-density lipopro-
ein cholesterol and triglyceride were decreased by 100mg/dL and
48mg/dL, respectively, with 2mg of pitavastatin instead of ator-
astatin, and the patient was discharged from the hospital with
o complications. Six months later, he was hospitalized with sta-
le effort angina. Coronary angiography showed 90% stenosis at
hemiddle portion of the circumﬂex artery, and stent implantation
as performed successfully. Elevations of inﬂammatory markers
nd triglyceride were not detected. Six months after the previous
oronary angioplasty, the patient died from panperitonitis with
eptic shock from perforation of a gastric ulcer. Pathohistology
f the right coronary artery from necropsy showed accumulation
f CD68-positive inﬂammatory cells in neointima and pericoronal
dipose tissue, indicating the existence of chronic coronary vasculi-
is involving adipose tissue.
iscussion
Inﬂammatory biomarkers are useful measures of synovial
nﬂammation, and alteration in inﬂammatory biomarkers is a pre-
ictor of clinical response to therapy. Premature mortality in RA
argely due to CVD is associated with the number of inﬂamed
oints. Tumor necrosis factor (TNF)- plays an important role in
he development of not only synovitis but also CVD in RA. It has
een reported that endothelial dysfunction is associated with sys-
emic inﬂammation and that anti-TNF- therapy, which is widely
sed for synovitis, improves endothelial function [5]. Therefore,
NF--mediated systemic inﬂammation should be suppressed in
A patients to prevent the development of CVD in addition to con-
rolling classical risk factors.
The high incidence of CVD in RA patients cannot be explained
nly by the accumulation of classical risk factors, and it has
herefore been believed that there is another pathway responsi-
le for accelerated atherogenesis in RA patients. The mechanisms
y which TNF- mediates inﬂammation of a joint have beenffort angina. RAPA, rheumatoid arthritis particle agglutination; ACS, acute coronary
e protein.
reported to involve increases in triglyceride level and plaque vul-
nerability [6]: TNF- is released from activated macrophages at
inﬂamed joints of synovitis, and then abundant circulating TNF-
 reduces endothelial lipoprotein lipase activity, leading to a
decrease in triglyceride catabolism and increase in circulating
triglyceride level. In addition, TNF- stimulates adipocyte lipoly-
sis and increases release of free fatty acid from peripheral tissues,
which augments triglyceride synthesis in the liver, leading to
an increase in circulating triglyceride levels. Moreover, activated
macrophages release matrix metalloproteinase, which accelerates
plaque vulnerability. This hypothesis may explain the TNF--
driven abrupt increase in serum triglyceride levels and increasedSerum triglyceride Plaque vulnerability
Fig. 4. Presumed mechanisms by which activation of synovitis accelerates plaque
vulnerability and increases serum triglyceride. TNF-, tumor necrosis factor-;
MMP, matrix metalloproteinase; TG, triglyceride; FFA, free fatty acid.
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temic inﬂammation accelerates vascular risk in rheumatoid arthritis. CirculationS. Yagi et al. / Journal of Ca
ur case, an abrupt increase in triglyceridewas seenwith exacerba-
ion of RA on the day of ACS onset even though other lipid markers
ncluding low-density lipoprotein cholesterol had been controlled;
owever, the change was not seen during effort angina, indicat-
ng that an abrupt increase in triglyceride could be a predictor of
laque rupture of coronary arteries. Therefore, triglyceride might
e a sensitive biomarker of activatedmacrophages and plaque vul-
erability, and an abrupt increase in triglyceride levelmight predict
he onset of ACS in patients with RA. Although large-scale clinical
tudies are needed to conﬁrm the hypothesis, RA patients with an
brupt increase in triglyceride might need intensive care includ-
ng anti-platelet and statin therapy for the prevention of coronary
laque rupture.
CRP level did not parallelwith triglyceride level before the onset
f ACS in our case, and it is therefore unknownwhether the degree
f plaque vulnerability was related to disease activity of RA rep-
esented by CRP. There is no evidence to support our speculation
ecause we could not measure TNF- level, and large-scale clini-
al studies with measurements of triglyceride, CRP, and TNF- are
herefore needed to conﬁrm the hypothesis.onﬂict of interest
The authors declare no conﬂict of interest.
[gy Cases 10 (2014) 54–57 57
Acknowledgment
Thisworkwas supported inpart by JSPSKAKENHIGrantNumber
25461131.
References
1] Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC,
Hazes JM. Factors associated with the development of vasculitis in rheuma-
toid arthritis: results of a case–control study. Ann Rheum Dis 1996;55:
190–2.
2] Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE,
Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women
diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
3] Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an
extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:
862–73.
4] Montecucco F, Mach F. Common inﬂammatory mediators orchestrate patho-
physiological processes in rheumatoid arthritis and atherosclerosis. Rheuma-
tology (Oxford) 2009;48:11–22.
5] Haraoui B, Liu PP, PappKA.Managing cardiovascular risk inpatientswith chronic
inﬂammatory diseases. Clin Rheumatol 2012;31:585–94.
6] Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how high-grade sys-2003;108:2957–63.
7] Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect
of disease modifying agents on the lipid proﬁles of patients with rheumatoid
arthritis. Ann Rheum Dis 1997;56:374–7.
